Temat: "Bone Density Conservation Agents" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Evaluation of growth, puberty, osteoporosis, and the response to long-term bisphosphonate therapy in four patients with osteoporosis-pseudoglioma syndrome.
Autorzy :: Karakilic-Ozturan E; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Altunoglu U; Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul University, Istanbul, Turkey.; Department of Medical Genetics, Koc University, School of Medicine, Istanbul, Turkey.
Ozturk AP; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Kardelen Al AD; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Yavas Abali Z; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Avci S; Department of Medical Genetics, Koc University, School of Medicine, Istanbul, Turkey.
Wollnik B; University Medical Center Göttingen, Institute of Human Genetics, Göttingen, Germany.
Poyrazoglu S; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Bas F; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.
Uyguner ZO; Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul University, Istanbul, Turkey.
Kayserili H; Department of Medical Genetics, Koc University, School of Medicine, Istanbul, Turkey.
Darendeliler F; Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul University, Istanbul, Turkey.; Pokaż więcej
Źródło :: American journal of medical genetics. Part A [Am J Med Genet A] 2022 Jul; Vol. 188 (7), pp. 2061-2070. Date of Electronic Publication: 2022 Apr 08.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/genetics
Bone Density/genetics ; Diphosphonates/therapeutic use ; Humans ; Low Density Lipoprotein Receptor-Related Protein-5/genetics ; Osteogenesis Imperfecta ; Puberty ; Retrospective Studies
SCR Disease Name :: Osteoporosis-pseudoglioma syndrome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.
Autorzy :: Gagliardi I; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.
Celico M; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.
Gamberini MR; Unit of Thalassaemia and Haemoglobinopathies Day Hospital, Regional HUB Centre, Department of Medicine, Azienda Ospedaliero Universitaria S. Anna, Cona, Ferrara, Italy.
Pontrelli M; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.
Fortini M; Unit of Thalassaemia and Haemoglobinopathies Day Hospital, Regional HUB Centre, Department of Medicine, Azienda Ospedaliero Universitaria S. Anna, Cona, Ferrara, Italy.
Carnevale A; Department of Interventional and Diagnostic Radiology, Arcispedale Sant'Anna, Ferrara, Italy.
Napoli N; Division of Endocrinology and Diabetes, University Campus Bio-Medico di Roma, Rome, Italy.
Zatelli MC; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy.
Ambrosio MR; Section of Endocrinology, Geriatrics & Internal Medicine, Dept of Medical Sciences, University of Ferrara, Via Fossato di Mortara 64/B, 44121, Ferrara, Italy. .; Pokaż więcej
Źródło :: Calcified tissue international [Calcif Tissue Int] 2022 Jul; Vol. 111 (1), pp. 56-65. Date of Electronic Publication: 2022 Mar 04.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporosis*/prevention & control
Teriparatide*/adverse effects
Teriparatide*/therapeutic use
beta-Thalassemia*/complications
beta-Thalassemia*/drug therapy
Adult ; Bone Density ; Female ; Fractures, Bone/chemically induced ; Humans ; Male ; Middle Aged ; Pain/complications ; Pain/etiology ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
Autorzy :: Hong N; Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Shin S; Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Lee S; Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Kim KJ; Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Rhee Y; Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. .; Pokaż więcej
Źródło :: Calcified tissue international [Calcif Tissue Int] 2022 Jul; Vol. 111 (1), pp. 47-55. Date of Electronic Publication: 2022 Feb 28.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Aged ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Female ; Humans ; Middle Aged ; Raloxifene Hydrochloride/pharmacology ; Raloxifene Hydrochloride/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Dipeptidyl Peptidase 3 Activity as a Promising Biomarker of Bone Fragility in Postmenopausal Women.
Autorzy :: Menale C; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.; Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Via Pansini 5, 80131 Napoli, Italy.
Tabacco G; Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.; Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, Italy.
Naciu AM; Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.; Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, Italy.
Schiavone ML; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
Cannata F; Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, Italy.
Morenghi E; Biostatistics Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.
Sobacchi C; IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy.; CNR-IRGB, Milan Unit, Via Fantoli 16/15, 20138 Milan, Italy.
Palermo A; Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.; Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, Italy.; Pokaż więcej
Źródło :: Molecules (Basel, Switzerland) [Molecules] 2022 Jun 19; Vol. 27 (12). Date of Electronic Publication: 2022 Jun 19.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*
Osteoporosis, Postmenopausal*/drug therapy
Osteoporosis, Postmenopausal*/genetics
Animals ; Biomarkers ; Bone Density ; Cross-Sectional Studies ; Denosumab/metabolism ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases ; Female ; Humans ; Kelch-Like ECH-Associated Protein 1/metabolism ; Mice ; NF-E2-Related Factor 2/metabolism ; Postmenopause ; Prospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Re: Long-term evaluation of anabolic and anti-resorptive agents in adults with familial osteoporosis due to pro205ala variant of the col1a1 gene.
Autorzy :: Dalgleish R; Department of Genetics and Genome Biology, University of Leicester, University Road, Leicester, LE1 7RH, UK. .; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jun; Vol. 33 (6), pp. 1403-1404. Date of Electronic Publication: 2022 Mar 02.
Typ publikacji :: Letter
MeSH Terms :: Anabolic Agents*
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/genetics
Adult ; Humans
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Letter of response to Professor Dalgleish regarding our paper Re: Long-term evaluation of anabolic and anti-resorptive agents in adults with familial osteoporosis due to pro205ala variant of the col1a1 gene.
Autorzy :: Tuck SP; Institute of Clinical and Translational Research, Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. .; Department of Rheumatology (S.P.T.), James Cook University Hospital, Middlesbrough, TS4 3BW, UK. .
Datta HK; Department of Blood Sciences (Pathology), James Cook University Hospital, Middlesbrough, TS4 3BW, UK.; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jun; Vol. 33 (6), pp. 1405. Date of Electronic Publication: 2022 Mar 02.
Typ publikacji :: Letter
MeSH Terms :: Anabolic Agents*
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis*/genetics
Adult ; Humans
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.
Autorzy :: Tominaga A; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan.
Wada K; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan. .
Okazaki K; Department of Orthopedic Surgery, Tokyo Women's Medical University, 8-1 Kawadacho Shinjuku-ku, Tokyo, Japan.
Nishi H; Hasuda Hospital, 1662-1 Negane Hasudashi, Saitama, Japan.
Terayama Y; Hasuda Hospital, 1662-1 Negane Hasudashi, Saitama, Japan.
Kodama Y; Ohara Clinic, 2-23-19 Ohara Setagaya-ku, Tokyo, Japan.
Kato Y; Kita Shinagawa 3rd Hospital, 3-3-7 Kitashinagawa Shinagawa-ku, Tokyo, Japan.; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jun; Vol. 33 (6), pp. 1265-1273. Date of Electronic Publication: 2022 Jan 21.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/chemically induced
Osteoporosis, Postmenopausal*/drug therapy
Antibodies, Monoclonal ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Diphosphonates/therapeutic use ; Female ; Humans ; Teriparatide/pharmacology ; Teriparatide/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Autorzy :: Cosman F; College of Physicians and Surgeons, Columbia University, 630 W 168th St, New York, NY, 10032, USA. .
Kendler DL; University of British Columbia, Vancouver, BC, Canada.
Langdahl BL; Aarhus University Hospital, Aarhus, Denmark.
Leder BZ; Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Lewiecki EM; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
Miyauchi A; Miyauchi Medical Center, Osaka, Japan.
Rojeski M; Amgen Inc., Thousand Oaks, CA, USA.
McDermott M; Amgen Inc., Thousand Oaks, CA, USA.
Oates MK; Amgen Inc., Thousand Oaks, CA, USA.
Milmont CE; Amgen Inc., Thousand Oaks, CA, USA.
Libanati C; UCB Pharma, Brussels, Belgium.
Ferrari S; Geneva University Hospital, Geneva, Switzerland.; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jun; Vol. 33 (6), pp. 1243-1256. Date of Electronic Publication: 2022 Feb 15.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Alendronate/pharmacology ; Alendronate/therapeutic use ; Antibodies, Monoclonal ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Female ; Humans ; Teriparatide/pharmacology ; Teriparatide/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
Autorzy :: Asano N; Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. .
Saito M; Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Kobayashi E; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Morii T; Department of Orthopaedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo, Japan.
Kikuta K; Department of Musculoskeletal Oncology and Orthopaedic Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Watanabe I; Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Anazawa U; Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Takeuchi K; Department of Orthopaedic Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama City, Kanagawa, Japan.
Suzuki Y; Department of Orthopaedic Surgery, Tachikawa Hospital, Tachikawa-shi, Tokyo, Japan.
Susa M; Department of Orthopaedic Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan.
Nishimoto K; Department of Orthopaedic Surgery, Kawasaki Municipal Ida Hospital, Kawasaki City, Kanagawa, Japan.
Ishii R; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Miyazaki N; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Mrioka H; Department of Orthopaedic Surgery, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan.
Kawai A; Department of Musculoskeletal Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Horiuchi K; Department of Orthopaedic Surgery, National Defense Medical College, Tokorozawa, Saitama, Japan.
Nakayama R; Department of Orthopaedic Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.; Pokaż więcej
Źródło :: Annals of surgical oncology [Ann Surg Oncol] 2022 Jun; Vol. 29 (6), pp. 3992-4000. Date of Electronic Publication: 2022 Feb 17.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Bone Density Conservation Agents*/therapeutic use
Bone Neoplasms*/drug therapy
Bone Neoplasms*/pathology
Bone Neoplasms*/surgery
Giant Cell Tumor of Bone*/drug therapy
Giant Cell Tumor of Bone*/pathology
Giant Cell Tumor of Bone*/surgery
Curettage/adverse effects ; Denosumab/adverse effects ; Denosumab/therapeutic use ; Humans ; Neoplasm Recurrence, Local/pathology ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Effects of Anti-Receptor Activator of Nuclear Factor Kappa B Ligand Antibody and Zoledronic Acid on Periapical Lesion Development in Mice.
Autorzy :: Ikeda M; Division of Endodontics, Department of Conservative Dentistry, Showa University School of Dentistry, Tokyo, Japan; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan.
Karakawa A; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan. Electronic address: .
Takizawa H; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan; Department of Orthodontics, Showa University School of Dentistry, Tokyo, Japan.
Azetsu Y; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan.
Sakai N; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan.
Chatani M; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan.
Suzuki N; Division of Endodontics, Department of Conservative Dentistry, Showa University School of Dentistry, Tokyo, Japan.
Takami M; Department of Pharmacology, Showa University School of Dentistry, Tokyo, Japan; Pharmacological Research Center, Showa University, Tokyo, Japan. Electronic address: .; Pokaż więcej
Źródło :: Journal of endodontics [J Endod] 2022 May; Vol. 48 (5), pp. 632-640. Date of Electronic Publication: 2022 Feb 15.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Bone Resorption*/drug therapy
Bone Resorption*/pathology
Bone Resorption*/prevention & control
Animals ; Inflammation/pathology ; Mice ; NF-kappa B ; Osteoclasts ; RANK Ligand ; Zoledronic Acid/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Emerging antiresorptive medications and their potential implications for dental surgeries.
Autorzy :: Aminoshariae A
Donaldson M
Horan M
Mackey SA
Kulild JC
Baur D; Pokaż więcej
Źródło :: Journal of the American Dental Association (1939) [J Am Dent Assoc] 2022 Jul; Vol. 153 (7), pp. 649-658. Date of Electronic Publication: 2022 Mar 08.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Bisphosphonate-Associated Osteonecrosis of the Jaw*/drug therapy
Bisphosphonate-Associated Osteonecrosis of the Jaw*/etiology
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Angiogenesis Inhibitors/adverse effects ; Denosumab/adverse effects ; Diphosphonates/adverse effects ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
Autorzy :: Khalid S; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. .; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. .
Calderon-Larranaga S; Family and Community Medicine Teaching Unit of Granada, Cartuja University Health Centre, Andalusian Health Service (SAS), Avda. Juan Pablo II, 18001, Granada, Spain.; Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, Turner Street, E1 2AB, UK.
Sami A; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
Hawley S; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; Bristol NIHR Biomedical Research Centre, Musculoskeletal Research Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK.
Judge A; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, Turner Street, E1 2AB, UK.; Bristol NIHR Biomedical Research Centre, Musculoskeletal Research Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB, UK.
Arden N; Arthritis Research UK Centre for Sport, Exercise, and Osteoarthritis, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
Van Staa TP; Centre for Health Informatics, University of Manchester, Vaughan House, Portsmouth Road, Manchester, M13 9PL, UK.; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, David de Wied building, Universiteitsweg 99, 3584 CG, Utrecht, Netherlands.
Cooper C; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK.; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.
Abrahamsen B; Odense Patient Data Explorative Network OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
Javaid MK; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.
Prieto-Alhambra D; Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK.; GREMPAL (Grup de Recerca en Malalties Prevalents de L'Aparell Locomotor) Research Group, CIBERFes and Idiap Jordi Gol Primary Care Research Institute, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Gran Via de Les Corts Catalanes, 591 Atico, 08007, Barcelona, Spain.; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jul; Vol. 33 (7), pp. 1579-1589. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :: Journal Article; Meta-Analysis
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Myocardial Infarction*/chemically induced
Myocardial Infarction*/epidemiology
Osteoporosis*/drug therapy
Alendronate/adverse effects ; Cohort Studies ; Databases, Factual ; Diabetes Mellitus/epidemiology ; Diphosphonates/adverse effects ; Humans ; Primary Health Care ; Renal Insufficiency, Chronic/epidemiology ; Risk Assessment ; Selective Estrogen Receptor Modulators/adverse effects ; Thiophenes/adverse effects ; United Kingdom/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
Autorzy :: Liu T; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Jiang L; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Food Science and Technology, Yunnan Agricultural University, Kunming 650201, China.
Xiang Z; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Li J; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Zhang Y; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Xiang T; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Food Science and Technology, Yunnan Agricultural University, Kunming 650201, China.
Wang W; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Li X; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Jia Y; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Food Science and Technology, Yunnan Agricultural University, Kunming 650201, China.
Huang X; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Food Science and Technology, Yunnan Agricultural University, Kunming 650201, China.
Lu X; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China.
Xu H; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China. Electronic address: .
Wang X; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; College of Science, Yunnan Agricultural University, Kunming 650201, China; State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Kunming 650201, China. Electronic address: .
Sheng J; Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China; State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Kunming 650201, China. Electronic address: .; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Jul; Vol. 151, pp. 113140. Date of Electronic Publication: 2022 May 20.
Typ publikacji :: Journal Article
MeSH Terms :: Bone Density Conservation Agents*/pharmacology
Bone Resorption*/metabolism
Eucalyptus Oil*/pharmacology
Osteoclasts*/drug effects
Osteoclasts*/metabolism
Animals ; Cell Differentiation/drug effects ; Down-Regulation ; Genes, src/physiology ; Mice ; Monoterpenes/pharmacology ; NF-kappa B/metabolism ; NFATC Transcription Factors/metabolism ; Osteogenesis/drug effects ; Osteoporosis/metabolism ; Protein-Tyrosine Kinases/metabolism ; RANK Ligand/metabolism ; RAW 264.7 Cells ; Signal Transduction/drug effects ; TNF Receptor-Associated Factor 6/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
Autorzy :: Benjawan S; Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand.
Nimitphong H; Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rama VI Road, Rajathevi, Bangkok 10400, Thailand.
Tragulpiankit P; Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand.
Musigavong O; Chao Phraya Abhaibhubejhr Hospital, Prachin Anuson Road, Tha Ngam, Mueang Prachinburi, Prachinburi 25000, Thailand.
Prathanturarug S; Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand.
Pathomwichaiwat T; Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand. Electronic address: .; Pokaż więcej
Źródło :: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2022 Jul; Vol. 101, pp. 154115. Date of Electronic Publication: 2022 Apr 20.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Bone Diseases, Metabolic*/drug therapy
Cissus*
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Biomarkers ; Bone Density ; Collagen Type I ; Double-Blind Method ; Female ; Humans ; Postmenopause
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Osteoporosis in children and adolescents: when to suspect and how to diagnose it.
Autorzy :: Ciancia S; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands. .
van Rijn RR; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Högler W; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Appelman-Dijkstra NM; Department of Internal Medicine, Subdivision of Endocrinology, Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.
Boot AM; Department of Pediatrics, Subdivision of Endocrinology, University Medical Center Groningen, Beatrix Children's Hospital, University of Groningen, Groningen, The Netherlands.
Sas TCJ; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.; Diabeter, Center for Pediatric and Adult Diabetes Care and Research, Rotterdam, The Netherlands.
Renes JS; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.; Pokaż więcej
Źródło :: European journal of pediatrics [Eur J Pediatr] 2022 Jul; Vol. 181 (7), pp. 2549-2561. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/diagnosis
Osteoporosis*/etiology
Spinal Fractures*/etiology
Adolescent ; Bone Density ; Child ; Humans ; Risk Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
Autorzy :: Ha J; Department of Internal Medicine, Division of Endocrinology and Metabolism, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim J; Department of Internal Medicine, Division of Endocrinology and Metabolism, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Jeong C; Department of Internal Medicine, Division of Endocrinology and Metabolism, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Republic of Korea.
Lim Y; Department of Internal Medicine, Division of General Internal Medicine, National University Bundang Hospital, Seongnam, Republic of Korea.
Kim MK; Department of Internal Medicine, Division of Endocrinology and Metabolism, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kwon HS; Department of Internal Medicine, Division of Endocrinology and Metabolism, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Song KH; Department of Internal Medicine, Division of Endocrinology and Metabolism, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kang MI; Department of Internal Medicine, Division of Endocrinology and Metabolism, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Baek KH; Department of Internal Medicine, Division of Endocrinology and Metabolism, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. .; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jul; Vol. 33 (7), pp. 1591-1599. Date of Electronic Publication: 2022 Apr 04.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*/complications
Osteoporosis, Postmenopausal*/drug therapy
Spinal Fractures*/etiology
Bone Density ; Denosumab/adverse effects ; Female ; Follow-Up Studies ; Humans ; Postmenopause ; Raloxifene Hydrochloride/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Autorzy :: Iki M; Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Electronic address: .
Fujimori K; Department of Health Administration and Policy, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Nakatoh S; Department of Orthopedic Surgery, Asahi General Hospital, 477 Tomari, Asahimachi, Shimo-Nikawa-gun, Toyama 939-0798, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Tamaki J; Department of Hygiene and Public Health, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Ishii S; Department of Regulatory Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachiouji, Tokyo 193-0392, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Okimoto N; Okimoto Clinic, 185-4 Kubi, Yutaka-machi, Kure, Hiroshima 734-0304, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Kamiya K; Department of Hygiene and Public Health, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Ogawa S; Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8511, Japan; National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan.; Pokaż więcej
Źródło :: Bone [Bone] 2022 Jul; Vol. 160, pp. 116396. Date of Electronic Publication: 2022 Mar 26.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Bone Density Conservation Agents*/therapeutic use
Hip Fractures*/drug therapy
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporosis*/epidemiology
Osteoporotic Fractures*/drug therapy
Osteoporotic Fractures*/epidemiology
Spinal Fractures*/chemically induced
Spinal Fractures*/epidemiology
Female ; Glucocorticoids/adverse effects ; Humans ; Insurance, Health ; Japan/epidemiology ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Autorzy :: Kellier-Steele N; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: Kellier_nicole_.
Casso D; IQVIA, Plymouth Meeting, PA, USA.
Anderson A; IQVIA, Plymouth Meeting, PA, USA.
Oliveria SA; IQVIA, Plymouth Meeting, PA, USA.
Motsko S; Eli Lilly and Company, Indianapolis, IN, USA.; Pokaż więcej
Źródło :: Bone [Bone] 2022 Jul; Vol. 160, pp. 116394. Date of Electronic Publication: 2022 Mar 19.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Bone Neoplasms*/drug therapy
Bone Neoplasms*/epidemiology
Osteoporosis*/chemically induced
Osteoporosis*/drug therapy
Osteoporosis*/epidemiology
Osteosarcoma*/drug therapy
Osteosarcoma*/epidemiology
Pharmacy*
Animals ; Bone Density ; Drug Labeling ; Humans ; Incidence ; Rats ; Registries ; Teriparatide/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Autorzy :: Wang R; Department of Diabetes and Endocrinology, Peninsula Health, 2 Hastings Road, Frankston, VIC, 3199, Australia. .
Renouf DA; Department of Diabetes and Endocrinology, Peninsula Health, 2 Hastings Road, Frankston, VIC, 3199, Australia.; Pokaż więcej
Źródło :: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Jul; Vol. 33 (7), pp. 1625-1629. Date of Electronic Publication: 2022 Mar 14.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Bone Neoplasms*/complications
Bone Neoplasms*/drug therapy
Breast Neoplasms*/complications
Breast Neoplasms*/drug therapy
Hypercalcemia*/chemically induced
Hypercalcemia*/drug therapy
Denosumab/adverse effects ; Female ; Humans ; Middle Aged ; Parathyroid Hormone/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report.
Autorzy :: Goh JKM; Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road Academia Building Level 4, Singapore, 119228, Singapore. .
Koh JSB; Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road Academia Building Level 4, Singapore, 119228, Singapore.
Ng ACM; Mount Elizabeth Medical Centre, The Endocrine Clinic, 3 Mount Elizabeth #15-04, Singapore, 228510, Singapore.
Png MA; Department of Diagnostic Radiology, Singapore General Hospital, Block 2, Level 1, Outram Road, Singapore, 169608, Singapore.
Howe TS; Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road Academia Building Level 4, Singapore, 119228, Singapore.; Pokaż więcej
Źródło :: Calcified tissue international [Calcif Tissue Int] 2022 Jul; Vol. 111 (1), pp. 96-101. Date of Electronic Publication: 2022 Feb 08.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Bone Density Conservation Agents*/adverse effects
Femoral Fractures*/chemically induced
Osteoporosis*/chemically induced
Denosumab/adverse effects ; Diphosphonates/adverse effects ; Female ; Femur ; Humans ; Middle Aged
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Bone Density Conservation Agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język